Chemometec A/S
F:CHY

Watchlist Manager
Chemometec A/S Logo
Chemometec A/S
F:CHY
Watchlist
Price: 44.92 EUR -2.01% Market Closed
Market Cap: €781.7m

Chemometec A/S
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Chemometec A/S
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Chemometec A/S
CSE:CHEMM
Net Income (Common)
kr177m
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
N/A
G
Gubra A/S
CSE:GUBRA
Net Income (Common)
kr1.7B
CAGR 3-Years
632%
CAGR 5-Years
166%
CAGR 10-Years
N/A
No Stocks Found

Chemometec A/S
Glance View

Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.

CHY Intrinsic Value
63 EUR
Undervaluation 29%
Intrinsic Value
Price €44.92

See Also

What is Chemometec A/S's Net Income (Common)?
Net Income (Common)
177m DKK

Based on the financial report for Dec 31, 2025, Chemometec A/S's Net Income (Common) amounts to 177m DKK.

What is Chemometec A/S's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
19%

Over the last year, the Net Income (Common) growth was 5%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett